ES2952644T3 - Compuesto adyuvante - Google Patents
Compuesto adyuvante Download PDFInfo
- Publication number
- ES2952644T3 ES2952644T3 ES12780309T ES12780309T ES2952644T3 ES 2952644 T3 ES2952644 T3 ES 2952644T3 ES 12780309 T ES12780309 T ES 12780309T ES 12780309 T ES12780309 T ES 12780309T ES 2952644 T3 ES2952644 T3 ES 2952644T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- antigen
- group
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543510P | 2011-10-05 | 2011-10-05 | |
| NL2007536A NL2007536C2 (en) | 2011-10-05 | 2011-10-05 | Adjuvant compound. |
| US201261615566P | 2012-03-26 | 2012-03-26 | |
| PCT/NL2012/050694 WO2013051936A1 (en) | 2011-10-05 | 2012-10-04 | Adjuvant compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952644T3 true ES2952644T3 (es) | 2023-11-02 |
Family
ID=48043964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12780309T Active ES2952644T3 (es) | 2011-10-05 | 2012-10-04 | Compuesto adyuvante |
Country Status (16)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| AU2014300503B2 (en) | 2013-06-28 | 2018-11-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| EP3148566B1 (en) | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
| CN107250103A (zh) | 2014-12-23 | 2017-10-13 | 玛格丽特·安妮·布林布尔 | 氨基酸缀合物和肽缀合物以及其用途 |
| IL298653A (en) | 2015-12-11 | 2023-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| WO2017145097A2 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| EP3552623A1 (en) | 2016-06-20 | 2019-10-16 | ISA Pharmaceuticals B.V | Formulation of a peptide vaccine |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| CN110650750A (zh) | 2017-04-04 | 2020-01-03 | 阿维迪科技公司 | 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途 |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| AU2020397499A1 (en) | 2019-12-07 | 2022-06-16 | Erasmus University Medical Center Rotterdam | Treatment of diseases related to hepatitis B virus |
| EP4100051A2 (en) | 2020-02-07 | 2022-12-14 | ISA Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| EP4138876A1 (en) | 2020-04-23 | 2023-03-01 | ISA Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| CN117730247A (zh) | 2021-07-12 | 2024-03-19 | Isa制药有限公司 | 复杂混合物中改善的物质定量 |
| WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
| AU2023361181A1 (en) | 2022-10-13 | 2025-05-22 | Isabella Pharma B.V. | Modified long peptides suitable for use in immunisation |
| WO2024149888A1 (en) | 2023-01-12 | 2024-07-18 | Isa Pharmaceuticals B.V. | Improved lipopeptide quantification |
| WO2025008085A1 (en) | 2023-07-05 | 2025-01-09 | Isa Pharmaceuticals B.V. | Immunotherapy for the treatment of prame-expressing cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| DE3937412A1 (de) * | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| BR0012069A (pt) | 1999-06-30 | 2002-08-27 | Corixa Corp | Composições e métodos para a terapia e diagnóstico de câncer pulmonar |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| NL1012739C2 (nl) | 1999-07-29 | 2001-01-30 | Maasland Nv | Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer. |
| AU2002219711B8 (en) | 2000-12-08 | 2006-03-02 | Academisch Ziekenhuis Leiden | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| MXNL04000056A (es) | 2004-06-30 | 2006-01-11 | Mario Alberto Aguilera Rico | Sistema de construccion terra acero. |
| AU2007284656A1 (en) * | 2006-08-14 | 2008-02-21 | Thymon, L.L.C. | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 |
| JP5649952B2 (ja) | 2007-03-26 | 2015-01-07 | アカデミシュ・ジーケンフイス・レイデン・エイチ．オー．デー．エヌ．・エルユーエムシーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ ｈ．ｏ．ｄ．ｎ． ＬＵＭＣ | Ｐｒａｍｅ由来ペプチド及びこれらを含んでいる免疫原性組成物 |
| CA2689536A1 (en) | 2007-05-31 | 2008-12-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
| CA3167595A1 (en) | 2007-05-31 | 2008-12-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| EA031379B1 (ru) * | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
-
2011
- 2011-10-05 NL NL2007536A patent/NL2007536C2/en active
-
2012
- 2012-10-04 KR KR1020147012025A patent/KR102053699B1/ko active Active
- 2012-10-04 EP EP12780309.6A patent/EP2763697B9/en active Active
- 2012-10-04 US US14/349,652 patent/US9314521B2/en active Active
- 2012-10-04 ES ES12780309T patent/ES2952644T3/es active Active
- 2012-10-04 MX MX2014004114A patent/MX356028B/es active IP Right Grant
- 2012-10-04 EA EA201490709A patent/EA030741B1/ru not_active IP Right Cessation
- 2012-10-04 BR BR112014008214-6A patent/BR112014008214B1/pt active IP Right Grant
- 2012-10-04 IN IN3325DEN2014 patent/IN2014DN03325A/en unknown
- 2012-10-04 WO PCT/NL2012/050694 patent/WO2013051936A1/en active Application Filing
- 2012-10-04 AU AU2012319265A patent/AU2012319265B2/en active Active
- 2012-10-04 SG SG11201401291XA patent/SG11201401291XA/en unknown
- 2012-10-04 JP JP2014534504A patent/JP6099210B2/ja active Active
- 2012-10-04 CN CN201280059738.4A patent/CN104244976B/zh active Active
- 2012-10-04 CA CA2886631A patent/CA2886631C/en active Active
-
2014
- 2014-04-03 IL IL231951A patent/IL231951B/en active IP Right Grant
-
2016
- 2016-03-07 US US15/062,589 patent/US9770506B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2952644T3 (es) | Compuesto adyuvante | |
| JP7179896B2 (ja) | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| ES2983085T3 (es) | Fusión que comprende un péptido de penetración celular, un multiepítopo y un agonista peptídico de TLR para el tratamiento de cáncer | |
| ES3035198T3 (en) | Cpg amphiphiles and uses thereof | |
| JP2024509935A (ja) | 免疫細胞療法における両親媒性物質の使用及びそのための組成物 | |
| AU2019351458A1 (en) | Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same | |
| US12016918B2 (en) | Peptide-containing adjuvant compounds having peg spacers | |
| NZ623869B2 (en) | Improved pam3cys-like lipopeptide adjuvant compound | |
| WO2023220634A2 (en) | Uses of amphiphiles in immune cell therapy and compositions therefor | |
| EA049338B1 (ru) | Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr |